Q3 Interim Report January 2021 – March 2021
Opening remarks The third quarter has been an intense and exciting period for Hamlet Pharma. In January, the first patients were included in the dose-escalation part of the Phase I/II trial. On May 10, the company announced the successful outcome of this study, where an initial data analysis had revealed a dramatic increase in the tumor response to increasing amounts of Alpha1H. The effect was measured both as shedding of cells and of tumor fragments into the urine as well as of pronounced changes in tumor tissue, with large areas of cells undergoing apoptosis or necrosis. DNA